T cell receptor specific for MOG35–55–MHC class II complexes (MOG35-55-specific TCR)

The T cell receptor (TCR) specific for MOG35–55–MHC class II complexes is a specialized immune receptor that plays a central role in the pathogenesis of autoimmune demyelinating diseases. It specifically recognizes the 35–55 peptide of myelin oligodendrocyte glycoprotein (MOG) when presented by MHC class II molecules, such as I-Ab in murine models or HLA-DR2 in humans (Source: 1.1.1, 1.3.3). Upon binding, this TCR triggers the activation of autoreactive CD4+ T cells, leading to their differentiation into pathogenic Th1 and Th17 subsets that infiltrate the central nervous system (Source: 1.4.1, 1.4.3). This inflammatory process results in demyelination and axonal damage, characteristic of Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE) (Source: 1.3.1). As a therapeutic target, this TCR is addressed through antigen-specific immunotherapies designed to induce peripheral tolerance or block the TCR-MHC interaction (Source: 1.1.2, 1.4.4). Investigational agents include recombinant TCR ligands (RTLs) like RTL342M, which act as soluble decoys or tolerogens, and TCR-like antibodies such as 2G10 that prevent T cell engagement (Source: 1.1.1, 1.4.5). Other approaches involve altered peptide ligands (APLs) and mannan-conjugated peptides that promote T cell anergy or the induction of regulatory T cells (Source: 1.1.3, 1.4.1). Targeting this specific TCR complex offers the potential for highly precise treatment of neuroinflammation while minimizing the risks associated with broad-spectrum immunosuppression (Source: 1.4.4).

Other names

2D2 TCRMOG-specific T cell receptorMyelin oligodendrocyte glycoprotein-specific T cell receptorMOG35-55-specific TCRAnti-MOG T cell receptor

Induction of antigen-specific T cell tolerance through anergy, clonal deletion, or regulatory T cell induction; competitive blocking of the TCR-MHC-peptide trimolecular complex formation.